Ligand Pharmaceuticals, Inc. is a US-based pharmaceutical company with a risk rating score of 24.5, placing it at a medium risk level. Specializing in biopharmaceuticals, Ligand focuses on developing and acquiring technologies to create innovative medicines. The company has partnerships and license agreements in the pharmaceutical and biotechnology sectors. Ligand's revenue streams include royalties from commercialized products, license and milestone payments, and the sale of its unique Captisol material. The company's business model emphasizes drug discovery, early-stage development, product reformulation, and strategic partnerships.